Dr. Geoffrey Shapiro

MD, PhD – Medical Oncologist

 

Profile

Dr. Geoffrey Shapiro

MD, University of Minnesota Medical School
Residency in Internal Medicine, Hennepin County Medical Center
Fellowship in Hematology & Oncology, University of Minnesota

Current Role At Neovita

Dr. Shapiro serves as Senior Oncology Advisor at NeoVita, contributing expertise in targeted therapies and clinical trial development.

Expertise & Specialization

•Targeted cancer therapies
• Cell cycle and checkpoint inhibitors
• Translational research in oncology
• Clinical trial leadership

Memberships & Affiliation

• American Association for Cancer Research (AACR)
• American Society of Clinical Oncology (ASCO)

Biography

Dr. Geoffrey Shapiro earned both his PhD (1987) and his MD (1988) from Weill Medical College of Cornell University. Dana-Farber Cancer Institute+2Bicycle Therapeutics+2 Following that, he did postgraduate training in Internal Medicine at Beth Israel Hospital, Boston, where he served as Chief Medical Resident. Dana-Farber Cancer Institute+1 He completed a fellowship in medical oncology at Dana-Farber Cancer Institute, during which his research focused on cell-cycle-related proteins in lung cancer. Dana-Farber Cancer Institute+2Bicycle Therapeutics+2. Dr. Shapiro is currently Director of the Early Drug Development Center at Dana-Farber, also serving as Senior Vice President of Developmental Therapeutics.He also serves as a medical oncologist here at neovita. He leads efforts in early-phase (Phase I) clinical trials, particularly those targeting cell cycle, DNA damage/repair, and related pathways. Dana-Farber Cancer Institute+2Bicycle Therapeutics+2 He is also a Professor of Medicine at Harvard Medical School. Dana-Farber Cancer Institute+2dfhcc.harvard.edu+2,

 

Career highlights & Achievements 

Dr. Geoffrey Shapiro has built a distinguished career at the forefront of cancer drug development, earning international recognition for his leadership in early-phase clinical trials and translational research. In 2019, he was honored with the International Congress on Targeted Anticancer Therapies (TAT) Honorary Award for Cancer Drug Development, highlighting his pioneering work in advancing novel targeted agents. His contributions have been instrumental in the clinical development of CDK inhibitors, DNA damage response modulators such as PARP inhibitors, and signal transduction inhibitors, with an emphasis on proof-of-mechanism studies and rational drug combinations. Beyond his scientific impact, he plays a vital role in shaping national research directions through the NCI-sponsored Experimental Therapeutics Clinical Trials Network (ETCTN), and his mentorship has guided the next generation of oncology researchers. His work has directly influenced the way solid tumors are approached in the clinic, bringing new therapies from laboratory concepts to patient care and significantly advancing the field of developmental therapeutics.

Contact Information

Websites & Profiles